31 recruiting. 31 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 31 | Recruiting 31 |
Follow Behavioral Symptoms: new trials by email Literature Review of Behavioral Symptoms trials Research Report on Behavioral Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression Lumateperone 42 mg - Bipolar Depression Depressed Phase, Obesity & Overweight | Phase 4 | Recruiting | Massachusetts General Hospital | 25 | 2026-09-09 | 2026-09-11 |
| Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities Deutetrabenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Recruiting | University Hospitals Cleveland Medical Center | 25 | 2026-06-22 | 2026-07-06 |
| Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE) Intravenous Esketamine, Crisis Response Planning (CRP), Enhanced Treatment as Usual (eTAU) - Suicide Prevention, Ketamine | Phase 4 | Recruiting | University of Sao Paulo | 478 | 2026-06-01 | 2026-09-16 |
| Comprehensive Toileting Program Glycerin Suppository, Behavioral strategies - Encopresis, ASD | Phase 4 | Recruiting | Emory University | 150 | 2026-06-01 | 2026-06-18 |
| Comparing Acupuncture With Medication to Reduce Depression, Anxiety and Comorbid Sleep Disorders in China Psychotropic Drugs, Acupuncture - Anxiety Depression, Sleep | Phase 4 | Recruiting | Duke Kunshan University | 180 | 2026-04-01 | 2026-07-29 |
| Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia Clostridium butyricum, placebo - Functional Dyspepsia, Probiotics | Phase 4 | Recruiting | Xijing Hospital of Digestive Diseases | 180 | 2026-03-26 | 2026-10-13 |
| Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants CNS Stimulant, Placebo, CNS Stimulant open label first phase - ADHD - Attention Deficit Disorder With Hyperactivity, Irritability | Phase 4 | Recruiting | Milton S. Hershey Medical Center | 136 | 2026-03-05 | 2026-04-20 |
| Esketamine With or Without Integration Therapy for Treatment-Resistant Depression Esketamine hydrochloride (intranasal), Integration Therapy - Treatment-resistant Depression (TRD) | Phase 4 | Recruiting | University of Puerto Rico | 20 | 2026-02-01 | 2026-01-27 |
| Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients Ketamine, standard general anesthesia - Orthopedic Trauma Surgery Patients, Postoperative Pain | Phase 4 | Recruiting | Texas Tech University Health Sciences Center | 90 | 2025-11-06 | 2026-03-24 |
| Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients Metformin Hydrochloride - Depression | Phase 4 | Recruiting | Fazaia Ruth Pfau Medical College | 140 | 2025-10-01 | 2025-09-19 |
| Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity Semaglutide Injectable Product, Placebo - Major Depressive Disorder | Phase 4 | Recruiting | Nordsjaellands Hospital | 116 | 2025-09-11 | 2026-02-06 |
| Algorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression Algorithm guided treatment (AGT), Treatment as usual (TAU) - Treatment Resistant Depression (TRD) | Phase 4 | Recruiting | Aalborg University Hospital | 80 | 2025-08-13 | 2026-04-27 |
| Identifying and Treating Depression in the Orthopaedic Trauma Population Fluoxetine 20 MG, Duloxetine 30 MG, Observation - Depression | Phase 4 | Recruiting | Wake Forest University Health Sciences | 100 | 2025-06-25 | 2026-05-22 |
| Evaluation of Speech and Voice Biomarkers in Association With Burnout Calmigo - Burnout, Burnout, Healthcare Workers | Phase 4 | Recruiting | Minneapolis Heart Institute Foundation | 200 | 2025-06-02 | 2026-08-24 |
| Establishing Mobile Transcranial Magnetic Stimulation Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression - Treatment Resistant Major Depression | Phase 4 | Recruiting | Medical University of South Carolina | 30 | 2025-05-10 | 2026-05-06 |
| Trazodone on NREM Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients 5-hydroxytryptamine balanced antidepressants trazodone, Citalopram hydrobromide combined with zolpidem - Depressed Insomniac Co-morbid Patients | Phase 4 | Recruiting | Tongji University | 60 | 2025-01-01 | 2025-02-19 |
| Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA). Monoglyceride Eicosapentaenoic acid (omega-3), Sunflower Oil - Brain Fog, Cognitive Health | Phase 4 | Recruiting | Samuel Fortin | 48 | 2024-11-06 | 2025-12-11 |
| Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression Transdermal estradiol, Progesterone, Transdermal placebo patch - Major Depressive Disorder | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 75 | 2024-09-02 | 2025-10-29 |
| Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity Contrave, Placebo, Diet Program - Obesity, Weight Loss | Phase 4 | Recruiting | The Royal's Institute of Mental Health Research | 40 | 2024-07-04 | 2025-07-24 |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms AXS-05, Bupropion - Major Depressive Disorder | Phase 4 | Recruiting | Axsome Therapeutics, Inc. | 350 | 2023-12-27 | 2025-01-23 |
Showing 20 of 31. Sign in to see all of them.
Depression (23) · Depressive Disorder, Major (8) · Anxiety Disorders (4) · Obesity (3) · Anhedonia (2) · Attention Deficit Disorder with Hyperactivity (2) · Bipolar Disorder (2) · Depressive Disorder, Treatment-Resistant (2) · Psychotic Disorders (2) · Aggression (1) · Brain Injuries, Traumatic (1) · Burnout, Psychological (1) · Caregiver Burden (1) · Delusions (1) · Depressive Disorder (1)
Behavior (31) · Mental Disorders (23) · Mood Disorders (11) · Pathological Conditions, Signs and Symptoms (11) · Depressive Disorder (10) · Signs and Symptoms (10) · Nervous System Diseases (6) · Neurologic Manifestations (5) · Neurobehavioral Manifestations (4) · Body Weight (3) · Central Nervous System Diseases (3) · Neurodevelopmental Disorders (3) · Nutrition Disorders (3) · Nutritional and Metabolic Diseases (3)
Esketamine (3) · Bupropion (2) · Central Nervous System Stimulants (2) · Ketamine (2) · Progesterone (2) · 1-eicosapentaenoylglycerol (1) · Acupuncture Therapy (1) · Adderall (1) · Buspirone (1) · Clinical Trials, Phase II as Topic (1) · Dexetimide (1) · Dexmethylphenidate Hydrochloride (1) · Docosahexaenoic Acids (1) · Duloxetine Hydrochloride (1) · Escitalopram (1)
Massachusetts General Hospital (3) · Emory University (2) · University of North Carolina, Chapel Hill (2) · Aalborg University Hospital (1) · Axsome Therapeutics, Inc. (1) · Duke Kunshan University (1) · Fazaia Ruth Pfau Medical College (1) · Laureate Institute for Brain Research, Inc. (1) · Matthew J O'Brien, PhD, BCBA-D (1) · Medical University of South Carolina (1) · Medical University of Vienna (1) · Milton S. Hershey Medical Center (1) · Minneapolis Heart Institute Foundation (1) · Nordsjaellands Hospital (1) · Royal North Shore Hospital (1)
United States (18) · China (4) · Canada (2) · Denmark (2) · Australia (1) · Austria (1) · Brazil (1) · Pakistan (1) · Puerto Rico (1)
Chris Sikes-Keilp, MD (1) · Claudia Nisa (1) · Crystal E Schiller, PhD (1) · Gabriel Dichter, PhD (1) · Gin Malhi (1) · Jennifer Felger, PhD (1) · Karen G Gonzalez-Martinez, MD, MSc (1) · Maj Vinberg, MD, PhD, DMSc (1) · Maria Ironside, DPhil (1) · Mark George, MD (1) · Matthew J O'Brien, PhD (1) · Max Evan Davis, MD (1) · Meghan K Wally, PhD (1) · Michael E Henry, MD (1) · Mindy Scheithauer, PhD (1)
PMID 17017829, PMID 19151617, PMID 19724732, PMID 20194822, PMID 20581790, PMID 21623982, PMID 21734685, PMID 22232986, PMID 23147210, PMID 24862430, PMID 26402520, PMID 29850262, PMID 31748286, PMID 32346286, PMID 35120288, PMID 36855177, PMID 38543297, PMID 38676734, PMID 41640857, PMID 42251276, PMID 42264114, PMID 42286600, PMID 9526970
2019 (1), R01HD115933 (1), R01MH122446 (1), R01MH128238 (1), R01MH132565 (1), R33MH121625 (1)